Correlation Engine 2.0
Clear Search sequence regions


  • 5’ agtccactgagtaccggagac- 3′ (1)
  • 5′- aaatgcaccatttcctgaga- 3′ (1)
  • 5′- atgcacatccttcgataagactg- 3′ (1)
  • 5′- cacctcatcgcagacatg- 3′ (1)
  • 5′- cacgaaactttgcccatagc- 3′ (1)
  • 5′- cccagtatttttatttctaaaggtgtt- 3′ (1)
  • 5′- ctgaggatctctggttgtggt- 3′ (1)
  • 5′- cttggcctccagacctagtaaagt- 3′ (1)
  • 5′- gagccgccgccgcaggaag- 3′ (1)
  • 5′- gagctttgcaggaagtttgc- 3′ (1)
  • 5′- gatgttctggagagccccg- 3′ (1)
  • 5′- gcaaagatcagagtgaaacag- 3′ (1)
  • 5′- gcaagaagcctctccttgaa- 3′ (1)
  • 5′- ggcaatttaacaatgtctgaaaagg- 3′ (1)
  • 5′- tccctttcttccacacgcagatga- 3′ (1)
  • aat (1)
  • acceptor (3)
  • actin (1)
  • Aldh1 (3)
  • anti- antibodies (1)
  • anti- igg (4)
  • antibodies (10)
  • apoptosis (2)
  • b cell (3)
  • behavior (6)
  • blue (2)
  • bone (2)
  • breast cancers (81)
  • breast tumors (18)
  • CAG 3 (1)
  • canada (2)
  • cancer stem cells (3)
  • cancers (60)
  • cases (3)
  • cat (5)
  • catalysis (2)
  • CD44 (3)
  • CD63 (4)
  • cdna (2)
  • cell extracts (4)
  • cell growth (13)
  • cellular (3)
  • cis Golgi matrix protein GM130 (1)
  • cmp sialic acid (3)
  • cMYC (1)
  • cofactors (4)
  • cohort (16)
  • colon (1)
  • colon cancer (3)
  • crystal violet (2)
  • culture cells (3)
  • cytosol (1)
  • d cells (1)
  • data analysis (4)
  • death receptor (1)
  • dnase (1)
  • donor (3)
  • e cadherin (4)
  • egf (1)
  • EGFR (1)
  • electron (7)
  • essential (1)
  • extracellular matrix (1)
  • extracellular space (4)
  • factor (7)
  • fitc (4)
  • free (16)
  • gal (1)
  • gene (26)
  • gene cancer (2)
  • gene networks (3)
  • glycans (10)
  • glycerol (1)
  • glycoproteins (7)
  • GM130 (2)
  • golgi complex (4)
  • growth factor (1)
  • hedgehog (4)
  • hepes (2)
  • HER2 (6)
  • human (41)
  • human cells (13)
  • hypoxia (5)
  • igg hrp (1)
  • intracellular protein (1)
  • lectin sambucus nigra (1)
  • lectins (6)
  • liver (2)
  • locale (1)
  • low (11)
  • lung (3)
  • lymphoblastoma (1)
  • massachusetts (2)
  • metastasis (2)
  • mortality (1)
  • mrnas (33)
  • mycoplasma (1)
  • myeloid leukemia (1)
  • n cadherin (3)
  • Nanog (3)
  • native (14)
  • normal breast (2)
  • ontario (2)
  • pair- comparison (1)
  • particles (32)
  • patient (23)
  • pcr (13)
  • phase (4)
  • phenol (1)
  • phenotypes (3)
  • PI3K (1)
  • plasmids (1)
  • platelets (1)
  • probability (1)
  • prognosis (2)
  • prostate (1)
  • protein c (2)
  • protein level (13)
  • random (28)
  • reagents (6)
  • real- time (11)
  • receptor (2)
  • rna sequences (1)
  • rnas (2)
  • sds page (1)
  • serum (19)
  • serum free media (1)
  • sialic acid (8)
  • sialoglycoprotein (1)
  • signal (1)
  • slides (6)
  • sodium (3)
  • ST3GAL6 (4)
  • st6gal 1 (2)
  • ST6GAL1 (257)
  • stage cancer (2)
  • stain (2)
  • student (6)
  • target genes (1)
  • taxonomy (1)
  • test kaplan– meier (3)
  • tnfr1 (1)
  • transit (2)
  • triton x- 100 (2)
  • TSG101 (4)
  • tubulin (3)
  • tumor- promotes (2)
  • western blot (13)
  • wst 8 (4)
  • β tubulin (2)
  • Sizes of these terms reflect their relevance to your search.

    The sialyltransferase ST6GAL1 that adds α2-6 linked sialic acids to N-glycans of cell surface and secreted glycoproteins is prominently associated with many human cancers. Tumor-native ST6GAL1 promotes tumor cell behaviors such as invasion and resistance to cell stress and chemo- and radio-treatments. Canonically, ST6GAL1 resides in the intracellular secretory apparatus and glycosylates nascent glycoproteins in biosynthetic transit. However, ST6GAL1 is also released into the extracellular milieu and extracellularly remodels cell surface and secreted glycans. The impact of this non-canonical extrinsic mechanism of ST6GAL1 on tumor cell pathobiology is not known. We hypothesize that ST6GAL1 action is the combined effect of natively expressed sialyltransferase acting cell-autonomously within the ER-Golgi complex and sialyltransferase from extracellular origins acting extrinsically to remodel cell-surface glycans. We found that shRNA knockdown of intrinsic ST6GAL1 expression resulted in decreased ST6GAL1 cargo in the exosome-like vesicles as well as decreased breast tumor cell growth and invasive behavior in 3D in vitro cultures. Extracellular ST6GAL1, present in cancer exosomes or the freely soluble recombinant sialyltransferase, compensates for insufficient intrinsic ST6GAL1 by boosting cancer cell proliferation and increasing invasiveness. Moreover, we present evidence supporting the existence novel but yet uncharacterized cofactors in the exosome-like particles that potently amplify extrinsic ST6GAL1 action, highlighting a previously unknown mechanism linking this enzyme and cancer pathobiology. Our data indicate that extracellular ST6GAL1 from remote sources can compensate for cellular ST6GAL1-mediated aggressive tumor cell proliferation and invasive behavior and has great clinical potential for extracellular ST6GAL1 as these molecules are in the extracellular space should be easily accessible targets. © 2022. The Author(s).

    Citation

    Nitai C Hait, Aparna Maiti, Rongrong Wu, Valerie L Andersen, Chang-Chieh Hsu, Yun Wu, Digantkumar G Chapla, Kazuaki Takabe, Michael E Rusiniak, Wiam Bshara, Jianmin Zhang, Kelley W Moremen, Joseph T Y Lau. Extracellular sialyltransferase st6gal1 in breast tumor cell growth and invasiveness. Cancer gene therapy. 2022 Jun 08;29(11):1662-1675

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 35676533

    View Full Text